Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
Pre-Market: 20:00
Taysha Gene Therapies Cash and Short Term Investments (Quarterly): 123.98M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 123.98M |
| December 31, 2023 | 143.94M |
| September 30, 2023 | 164.28M |
| June 30, 2023 | 45.08M |
| March 31, 2023 | 63.42M |
| December 31, 2022 | 87.88M |
| September 30, 2022 | 34.31M |
| June 30, 2022 | 66.24M |
| Date | Value |
|---|---|
| March 31, 2022 | 96.63M |
| December 31, 2021 | 149.10M |
| September 30, 2021 | 188.78M |
| June 30, 2021 | 197.37M |
| March 31, 2021 | 228.68M |
| December 31, 2020 | 251.25M |
| September 30, 2020 | 278.63M |
| June 30, 2020 | 11.20M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
11.20M
Minimum
Jun 2020
278.63M
Maximum
Sep 2020
133.17M
Average
133.96M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 95.20M |
| Lifecore Biomedical Inc | 19.09M |
| Relmada Therapeutics Inc | 83.61M |
| ACADIA Pharmaceuticals Inc | 470.52M |
| Cyclacel Pharmaceuticals Inc | 3.378M |